[Primitive myxoid melanoma: An unusual histological aspect].

Mélanome myxoïde primitif : une forme histologique inhabituelle.

Journal

Annales de dermatologie et de venereologie
ISSN: 0151-9638
Titre abrégé: Ann Dermatol Venereol
Pays: France
ID NLM: 7702013

Informations de publication

Date de publication:
May 2019
Historique:
received: 16 07 2018
revised: 21 09 2018
accepted: 30 01 2019
pubmed: 27 3 2019
medline: 27 12 2019
entrez: 27 3 2019
Statut: ppublish

Résumé

Myxoid melanoma is a rare variant of melanoma that must be recognised. Herein we describe a new metastatic case. A 78-year-old woman consulted for a firm, pinkish nodule measuring 25mm and present for six months on her left leg. Analysis of the biopsy revealed achromic fusiform tumour cells separated by large myxoid plaques. Labeling of SOX10, HMB45 and PS100 was diffuse and of moderate to strong intensity. A diagnosis of myxoid melanoma was considered, with Breslow thickness of 9mm. Surgery was carried out with a 2-cm margin and confirmed the diagnosis. Dermatological follow-up at one year revealed metastatic spread to the ganglia, pleura, liver and bone. Few cases of primary myxoid melanoma have been described, and the condition is probably underdiagnosed. The classic clinical presentation of this condition consists of a solitary achromic nodule found chiefly on the limbs. The microscopic appearance is relatively non-specific. Immunohistochemical analysis may indicate melanocytic involvement: cells exhibit expression of SOX10, diffuse expression of protein S100, and less consistent and more variable expression of HMB45. The increasingly common use of anti-SOX10 is of value since it is expressed in the nucleus of melanocytes. Mastocytes and TGF-ß secretion appear to be involved in myxoid stroma production. In the absence of specific codification, management of myxoid melanoma is comparable to that of other types of melanoma. There is uncertainty about the prognosis, with the involvement of TGF-ß possibly indicating the aggressive potential of this type of tumour.

Sections du résumé

BACKGROUND BACKGROUND
Myxoid melanoma is a rare variant of melanoma that must be recognised. Herein we describe a new metastatic case.
PATIENTS AND METHODS METHODS
A 78-year-old woman consulted for a firm, pinkish nodule measuring 25mm and present for six months on her left leg. Analysis of the biopsy revealed achromic fusiform tumour cells separated by large myxoid plaques. Labeling of SOX10, HMB45 and PS100 was diffuse and of moderate to strong intensity. A diagnosis of myxoid melanoma was considered, with Breslow thickness of 9mm. Surgery was carried out with a 2-cm margin and confirmed the diagnosis. Dermatological follow-up at one year revealed metastatic spread to the ganglia, pleura, liver and bone.
DISCUSSION CONCLUSIONS
Few cases of primary myxoid melanoma have been described, and the condition is probably underdiagnosed. The classic clinical presentation of this condition consists of a solitary achromic nodule found chiefly on the limbs. The microscopic appearance is relatively non-specific. Immunohistochemical analysis may indicate melanocytic involvement: cells exhibit expression of SOX10, diffuse expression of protein S100, and less consistent and more variable expression of HMB45. The increasingly common use of anti-SOX10 is of value since it is expressed in the nucleus of melanocytes. Mastocytes and TGF-ß secretion appear to be involved in myxoid stroma production. In the absence of specific codification, management of myxoid melanoma is comparable to that of other types of melanoma. There is uncertainty about the prognosis, with the involvement of TGF-ß possibly indicating the aggressive potential of this type of tumour.

Identifiants

pubmed: 30910333
pii: S0151-9638(19)30055-9
doi: 10.1016/j.annder.2019.01.015
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Melanoma-Specific Antigens 0
PMEL protein, human 0
S100 Proteins 0
SOX10 protein, human 0
SOXE Transcription Factors 0
gp100 Melanoma Antigen 0

Types de publication

Case Reports Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

372-376

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

C Capelle (C)

Université de Lille, Inserm U1189, service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowki, 59000 Lille, France. Electronic address: clemcapelle@hotmail.fr.

L Scherman (L)

Laboratoire d'anatomie et de pathologie, centre de Biopathologie, CHRU de Lille, 59037 Lille cedex, France.

A Gerard (A)

Université de Lille, Inserm U1189, service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowki, 59000 Lille, France.

C Vicentini (C)

Université de Lille, Inserm U1189, service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowki, 59000 Lille, France.

M Levavasseur (M)

Université de Lille, Inserm U1189, service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowki, 59000 Lille, France.

O Carpentier (O)

Service de médecine interne, hôpital Victor-Provo, centre hospitalier de Roubaix, 59056 Roubaix cedex, France.

L Mortier (L)

Université de Lille, Inserm U1189, service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowki, 59000 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH